公开(公告)号：US09469637B2

公开(公告)日：2016-10-18

申请号：US14397066

申请日：2013-04-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoshi Mikami ,  Shinji Nakamura ,  Tomoko Ashizawa ,  Shigekazu Sasaki ,  Takahiko Taniguchi ,  Izumi Nomura ,  Masanori Kawasaki

IPC: C07D241/36 ,  C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K9/20 ,  A61K31/498 ,  A61K31/555 ,  C07D519/00 ,  C07F7/1804

Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like.The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US09527841B2

公开(公告)日：2016-12-27

申请号：US14414020

申请日：2013-07-12

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shinji Nakamura ,  Satoshi Mikami ,  Kawasaki Masanori ,  Izumi Nomura ,  Tomoko Ashizawa ,  Takahiko Taniguchi

IPC: C07D241/38 ,  C07D471/04 ,  C07D235/16

CPC classification number: C07D471/04 ,  C07D235/16

Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like.The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

Abstract translation: 本发明提供具有PDE2A选择性抑制作用的化合物，其可用作预防或治疗精神分裂症，阿尔茨海默氏病等。 本发明是由式（1）表示的化合物：其中每个符号如说明书中所述或其盐。

公开(公告)号：US10017508B2

公开(公告)日：2018-07-10

申请号：US15264213

申请日：2016-09-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoshi Mikami ,  Shinji Nakamura ,  Tomoko Ashizawa ,  Shigekazu Sasaki ,  Takahiko Taniguchi ,  Izumi Nomura ,  Masanori Kawasaki

IPC: C07D241/36 ,  A61K31/498 ,  C07D471/04 ,  C07D519/00 ,  A61K9/20 ,  A61K31/555 ,  C07F7/18

CPC classification number: C07D471/04 ,  A61K9/20 ,  A61K31/498 ,  A61K31/555 ,  C07D519/00 ,  C07F7/1804

Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like.The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20150158863A1

公开(公告)日：2015-06-11

申请号：US14414020

申请日：2013-07-12

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shinji Nakamura ,  Satoshi Mikami ,  Kawasaki Masanori ,  Izumi Nomura ,  Tomoko Ashizawa ,  Takahiko Taniguchi

IPC: C07D471/04

CPC classification number: C07D471/04 ,  C07D235/16

Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like.The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

Abstract translation: 本发明提供具有PDE2A选择性抑制作用的化合物，其可用作预防或治疗精神分裂症，阿尔茨海默氏病等。 本发明是由式（1）表示的化合物：其中每个符号如说明书中所述或其盐。

公开(公告)号：US10214508B2

公开(公告)日：2019-02-26

申请号：US15318552

申请日：2015-06-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masaki Ogino ,  Eiji Kimura ,  Shinkichi Suzuki ,  Tomoko Ashizawa ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Ryosuke Arai

IPC: C07D401/10 ,  C07D401/14 ,  C07D405/14 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  C07D213/81 ,  C07D405/12

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.

公开(公告)号：US20160159808A1

公开(公告)日：2016-06-09

申请号：US14907139

申请日：2014-07-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masanori Kawasaki ,  Satoshi Mikami ,  Shinji Nakamura ,  Nobuyuki Negoro ,  Shuhei Ikeda ,  Izumi Nomura ,  Tomoko Ashizawa ,  Toshihiro Imaeda ,  Masaki Seto ,  Shigekazu Sasaki ,  Shogo Marui ,  Takahiko Taniguchi

IPC: C07D487/04 ,  C07D498/08 ,  C07D491/08 ,  C07D471/04 ,  C07D473/00

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D473/00 ,  C07D491/08 ,  C07D498/08

Abstract: A compound represented by the formula (I): wherein each symbol is as described in the SPECIFICATION, or a salt thereof has a PDE2A inhibitory action, and is useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like.

Abstract translation: 由式（I）表示的化合物：其中每个符号如说明书所述，或其盐具有PDE2A抑制作用，并且可用作精神分裂症，阿尔茨海默氏病等的预防或治疗药物。